PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-19.90%
Both companies show declining cash positions (-19.90% vs AGEN's -38.89%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-19.90%
Cash + STI yoy 1.25-1.5x AGEN's -15.77%. Bruce Berkowitz would check if the firm is preparing for expansions or simply hoarding.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.69%
Similar yoy growth to AGEN's -17.62%. Walter Schloss notes comparable short-term expansions. Investigate quality of these assets.
6.10%
Below half AGEN's 15.08%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both AGEN and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.84%
Below half of AGEN's -2.24%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-18.44%
1.25-1.5x AGEN's -12.53%. Bruce Berkowitz sees a stronger asset build. Check if it's producing returns.
65.60%
Less than half of AGEN's 142.93%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Above 1.5x AGEN's -9.59%. Michael Burry sees a major discrepancy in short-term leverage. Check coverage and liquidity carefully.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
≥ 1.5x AGEN's -52.98%. David Dodd sees stronger subscription/prepayment demand.
-13.55%
Less than half of AGEN's -64.17%. David Dodd sees fewer expansions in other current obligations.
-8.01%
50-75% of AGEN's -15.94%. Bruce Berkowitz notes the firm keeps current liabilities growth relatively low.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.01%
Similar yoy to AGEN's -8.91%. Walter Schloss sees parallel expansions in total liabilities.
7.31%
Above 1.5x AGEN's 0.05%. Michael Burry suspects heavy new equity expansion or dilution.
-7.62%
≥ 1.5x AGEN's -1.23%. David Dodd sees higher yoy retained profits than competitor.
-130.04%
Less than half of AGEN's -953.17%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-45.22%
≥ 1.5x AGEN's -15.20%. David Dodd sees stronger capital base growth than competitor.
-18.44%
1.25-1.5x AGEN's -12.53%. Bruce Berkowitz checks if expansions are well-justified by ROI.
-100.00%
≥ 1.5x AGEN's -0.16%. David Dodd sees far stronger investment expansions than competitor.
-100.00%
Above 1.5x AGEN's -9.59%. Michael Burry sees a major jump. Investigate leverage rationale.
19.60%
Less than half of AGEN's 42.82%. David Dodd sees better deleveraging or stronger cash buildup than competitor.